Is it safe to give an 82-year-old patient Amitiza (lubiprostone) 24 µg twice daily?

Yes, Amitiza 24 µg twice daily is safe for an 82-year-old patient with chronic idiopathic constipation

The FDA-approved dose of lubiprostone (Amitiza) 24 µg twice daily is safe and effective in elderly patients aged 65 and older, with efficacy comparable to younger populations and a notably lower rate of nausea (19% vs 29% in the overall population). 1

Evidence Supporting Safety in Elderly Patients

The 2023 AGA-ACG clinical practice guidelines specifically address elderly use, noting that efficacy in persons 65 years and older is comparable with the overall study population 2. The FDA drug label provides reassuring data from clinical trials where:

• 16% of patients were ≥65 years old and 4% were ≥75 years old in chronic idiopathic constipation studies
• Elderly patients experienced a lower rate of nausea (19%) compared to the overall population (29%) 1
• The safety profile in elderly patients was consistent with the overall study population across all indications 1

Dosing Considerations

Standard dosing of 24 µg twice daily is appropriate unless your patient has:

• Moderate hepatic impairment (Child-Pugh B): Reduce to 16 µg twice daily
• Severe hepatic impairment (Child-Pugh C): Reduce to 8 µg twice daily 1
• No dose adjustment needed for renal insufficiency (systemic absorption is negligible) 2

Expected Benefits

Your 82-year-old patient can expect:

• Increased spontaneous bowel movements by approximately 2 per week (MD 1.98,95% CI 1.17-2.79) 2
• Response within 24-48 hours in the majority of patients 2
• Improved stool consistency and reduced straining 2
• Responder rate of 67% (RR 1.67,95% CI 1.36-2.06) 2

Safety Profile and Monitoring

Common adverse events to counsel about:

• Nausea (19% in elderly): Usually mild-to-moderate, dose-dependent, reduced when taken with food and water; leads to discontinuation in only 5% 2, 1
• Diarrhea (12%): May lead to discontinuation in 2% of patients 2
• No serious adverse events were significantly increased (RR 1.22,95% CI 0.62-2.42) 2

Important safety considerations specific to elderly patients:

• Monitor for syncope/hypotension: Rare but reported, especially if patient has concomitant diarrhea, vomiting, or takes blood pressure medications 1
• Dyspnea (3%): Acute onset within 30-60 minutes of first dose, usually resolves within hours; instruct patient to contact you if this occurs 1
• No electrolyte monitoring required: No clinically significant changes in serum electrolytes observed 2

Contraindications

Do not use if patient has:

• Known or suspected mechanical GI obstruction 2

Implementation Strategy

Optimize tolerability by:

• Taking with food and water to minimize nausea 2
• Starting at full dose (24 µg twice daily) unless hepatic impairment present
• Counseling that effects typically manifest within 2 days 2
• No duration limit specified in drug label, though clinical trials were 4 weeks 2

Guideline Recommendation Context

The 2023 AGA-ACG guidelines provide a conditional recommendation for lubiprostone (low certainty of evidence) in adults with CIC who do not respond to OTC agents 2. This is a weaker recommendation compared to linaclotide (strong recommendation, moderate certainty), but the elderly-specific safety data and lower nausea rate in this age group make lubiprostone a reasonable choice for your 82-year-old patient.

The key advantage in elderly patients is the lower nausea rate and comparable efficacy, making this a safe and appropriate choice for chronic constipation management.